0001209191-23-016507.txt : 20230306 0001209191-23-016507.hdr.sgml : 20230306 20230306185556 ACCESSION NUMBER: 0001209191-23-016507 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230306 FILED AS OF DATE: 20230306 DATE AS OF CHANGE: 20230306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Monohon Ted CENTRAL INDEX KEY: 0001606905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38890 FILM NUMBER: 23710505 MAIL ADDRESS: STREET 1: C/O FANTEX, INC. STREET 2: 330 TOWNSEND ST., SUITE 234 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Quince Therapeutics, Inc. CENTRAL INDEX KEY: 0001662774 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 901024039 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-910-5717 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 1250 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Cortexyme, Inc. DATE OF NAME CHANGE: 20160104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-06 0 0001662774 Quince Therapeutics, Inc. QNCX 0001606905 Monohon Ted C/O QUINCE THERAPEUTICS, INC. 601 GATEWAY BLVD., SUITE 1250 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Accounting Officer & VP Common Stock 2023-03-06 4 S 0 1871 0.98 D 27440 D Represents shares sold to satisfy tax withholding obligations that arose in connection with the vesting of 4,250 shares of Restricted Stock Units granted on March 3, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2022. /s/ Ted Monohon 2023-03-06